Hostname: page-component-cd9895bd7-p9bg8 Total loading time: 0 Render date: 2024-12-26T00:45:37.140Z Has data issue: false hasContentIssue false
  • English
  • Français

D2 receptor occupancy following lurasidone treatment in patients with schizophrenia or schizoaffective disorder

Published online by Cambridge University Press:  30 September 2013

Steven G. Potkin ,
David B. Keator ,
Marilyn L. Kesler-West ,
Dana D. Nguyen ,
Theo. G. M. van Erp ,
Jogeshwar Mukherjee ,
Nikunj Shah  and
Adrian Preda
Steven G. Potkin*
Affiliation:
University of California–Irvine, School of Medicine, Irvine, California, USA
David B. Keator
Affiliation:
University of California–Irvine, School of Medicine, Irvine, California, USA
Marilyn L. Kesler-West
Affiliation:
University of California–Irvine, School of Medicine, Irvine, California, USA
Dana D. Nguyen
Affiliation:
University of California–Irvine, School of Medicine, Irvine, California, USA
Theo. G. M. van Erp
Affiliation:
University of California–Irvine, School of Medicine, Irvine, California, USA
Jogeshwar Mukherjee
Affiliation:
University of California–Irvine, School of Medicine, Irvine, California, USA
Nikunj Shah
Affiliation:
University of California–Irvine, School of Medicine, Irvine, California, USA
Adrian Preda
Affiliation:
University of California–Irvine, School of Medicine, Irvine, California, USA
*
*Address for correspondence: Steven G. Potkin, MD, Professor of Psychiatry and Human Behavior, Robert R. Sprague Chair in Brain Imaging, University of California–Irvine, 5251 California Avenue, Suite 240, Irvine, CA 92617, USA. (Email [email protected])
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective/Introduction

Lurasidone is an atypical antipsychotic medication approved for the treatment of schizophrenia over a dose range of 40–160 mg/day. This study examined D2 receptor occupancy and its association with clinical improvement and side effects in patients with schizophrenia or schizoaffective disorder following repeated doses of 80, 120, or 160 mg/day of lurasidone.

Methods

Twenty-five patients with The Diagnostic and Statistical Manual of Mental Disorders, 4th ed. (DSM-IV) diagnoses of schizophrenia or schizoaffective disorder were washed out of their antipsychotic medications (5 half-lives) and randomly assigned to 80, 120, or 160 mg/day of lurasidone. Subjects were imaged with 18F-fallypride at baseline and at steady-state lurasidone treatment to determine D2 receptor occupancy.

Results

Blood lurasidone concentration (plus major metabolite), but not dose, significantly correlated with D2 receptor occupancy. D2 receptor occupancy in several subcortical structures is associated with positive but not negative symptom improvement or the presence of movement symptoms.

Discussion

Blood concentrations greater than 70 ng/mL may be required to achieve a 65% occupancy level in subcortical areas. Intersubject blood concentrations at fixed dose were highly variable and may account for the lack of dose correlations.

Conclusions

Positron emission tomography (PET) occupancy data suggest that greater than 65% occupancy can be achieved across the dose range of 80–160 mg/day and that some patients require higher doses to achieve antipsychotic efficacy; this finding supports prior randomized clinical trial results.

Keywords

brain imagingD2 receptorLurasidoneOccupancyPETschizoaffectiveSchizophrenia
Type
Original Research
Information
CNS Spectrums , Volume 19 , Issue 2 , April 2014 , pp. 176 - 181
Copyright
Copyright © Cambridge University Press 2013 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

This investigator-initiated study was funded by Sunovion Pharmaceuticals.

References

1. Mukherjee, J, Yang, ZY, Brown, T, etal. Preliminary assessment of extrastriatal dopamine D-2 receptor binding in the rodent and nonhuman primate brains using the high affinity radioligand, 18F-fallypride. Nucl Med Biol. 1999; 26(5): 519–527.Google Scholar
2. Nakamura, M, Ogasa, M, Guarino, J, etal. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. J Clin Psychiatry. 2009; 70(6): 829–836.Google Scholar
3. Meyer, JM, Loebel, AD, Schweizer, E. Lurasidone: a new drug in development for schizophrenia. Expert Opin Investig Drugs. 2009; 18(11): 1715–1726.Google Scholar
4. Ishibashi, T, Horisawa, T, Tokuda, K, etal. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J Pharmacol Exp Ther. 2010; 334(1): 171–181.Google Scholar
5. Tarazi, FI, Stahl, SM. Iloperidone, asenapine and lurasidone: a primer on their current status. Expert Opin Pharmacother. 2012; 13(13): 1911–1922.Google Scholar
6. Mukherjee, J, Christian, BT, Dunigan, KA, etal. Brain imaging of 18F-fallypride in normal volunteers: blood analysis, distribution, test-retest studies, and preliminary assessment of sensitivity to aging effects on dopamine D-2/D-3 receptors. Synapse. 2002; 46(3): 170–188.CrossRefGoogle ScholarPubMed
7. Nordström, AL, Farde, L, Wiesel, FA, etal. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol Psychiatry. 1993; 33(4): 227–235.Google Scholar
8. Citrome, L. Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic. Int J Clin Pract. 2011; 65(2): 189–210.Google Scholar
9. Meltzer, HY, Cucchiaro, J, Silva, R, etal. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study. Am J Psychiatry. 2011; 168(9): 957–967.CrossRefGoogle ScholarPubMed
10. Loebel, A, Cucchiaro, J, Sarma, K, etal. Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial. Schizophr Res. 2013; 145(1–3): 101–109.Google Scholar
11. Koo, TS, Kim, SJ, Lee, J, etal. Quantification of lurasidone, an atypical antipsychotic drug, in rat plasma with high-performance liquid chromatography with tandem mass spectrometry. Biomed Chromatogr. 2011; 25(12): 1389–1394.Google Scholar
12. Chouinard, G, Margolese, HC. Manual for the extrapyramidal symptom rating scale (ESRS). Schizophr Res. 2005; 76(2–3): 247–265.Google Scholar
13. Montgomery, SA, Asberg, M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979; 134(4): 382–389.CrossRefGoogle ScholarPubMed
14. Guy, W. Clinical Global Impression Scale: The ECDEU Assessment Manual for Psychopharmacology—Revised. Volume DHEW, Publ. No. ADM 76, 1976; Vol. 338: 218–222.CrossRefGoogle Scholar
15. Kay, SR, Fiszbein, A, Opler, LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987; 13(2): 261–276.Google Scholar
16. Sossi, V, de Jong, HWAM, Barker, WC, etal. The second generation HRRT—a multi-centre scanner performance investigation. In: Nuclear Science Symposium Conference Record, 2005. New York: IEEE; 2005: 2195–2199.Google Scholar
17. Hong, IK, Chung, ST, Kim, HK, etal. Fast forward projection and backward projection algorithm using SIMD. In: Nuclear Science Symposium Conference Record, 2006. New York: IEEE; 2006: 3361–3368.CrossRefGoogle Scholar
18. Hong, I, Burbar, Z, Michel, C. True 3D iterative scatter correction for small bore long axial FOV scanner. In: Nuclear Science Symposium and Medical Imaging Conference (NSS/MIC), 2011. New York: IEEE; 2011: 3736–3738.Google Scholar
19. Logan JFowler, JS, Volkow, ND, etal. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab. 1996; 16(5): 834–840.CrossRefGoogle Scholar
20. Wong, DF, Kuwabara, H, Brašić, JR, etal. Determination of dopamine D2 receptor occupancy by lurasidone using positron emission tomography in healthy male subjects. Psychopharmacology (Berl). In press. DOI: 10.1007/s00213-013-3103-z.Google Scholar
21. Kapur, S, Zipursky, R, Jones, C, Remington, G, Houle, S. Relationship between dopamine D2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry. 2000; 157(4): 514–520.Google Scholar
22. Farde, L, Wiesel, FA, Halldin, C, Sedvall, G. Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry. 1988; 45(1): 71–76.Google Scholar
23. Mamo, D, Kapur, S, Shammi, CM, etal. A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. Am J Psychiatry. 2004; 161(5): 818–825.Google Scholar
24. Gründer, G, Landvogt, C, Vernaleken, I, etal. The striatal and extrastriatal D2/D3 receptor-binding profile of clozapine in patients with schizophrenia. Neuropsychopharmacology. 2005; 31(5): 1027–1035.CrossRefGoogle Scholar
25. Gründer, G, Fellows, C, Janouschek, H, etal. Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18F] fallypride PET study. Am J Psychiatry. 2008; 165(8): 988–995.Google Scholar
26. Rahmioglu, N, Heaton, J, Clement, G, etal. Genetic epidemiology of induced CYP3A4 activity. Pharmacogenet Genomics. 2011; 21(10): 642–651.Google Scholar
27. Pinborg, LH, Videbaek, C, Ziebell, M, etal. [123I]epidepride binding to cerebellar dopamine D2/D3 receptors is displaceable: implications for the use of cerebellum as a reference region. Neuroimage. 2007; 34(4): 1450–1453.CrossRefGoogle Scholar